AIM ImmunoTech Reports Q3 2025 Financials and Highlights Progress in Pancreatic Cancer Program

AIM ImmunoTech reported Q3 2025 financial results with cash, cash equivalents, and marketable investments of $2.4 million. Research and development expenses were $607,000, and general and administrative expenses were $1.8 million. The net loss from operations was $3.3 million, or $(1.57) per share. The company highlighted positive clinical and operational execution, with a focus on its pancreatic cancer clinical program.